Fellström B, Butz M, Danielson B G, Ljunghall S
Scand J Urol Nephrol. 1985;19(2):125-7. doi: 10.3109/00365598509180239.
Among the various treatments for renal calcium stone disease, none has been documented to reduce urinary oxalate. Methenamine-hippurate (Hiprex) has been used extensively in the treatment of urinary tract infections and from micropuncture studies in the rat, using para-aminohippurate, it could be expected to reduce the renal secretion of oxalate. A daily dose of 3 g was given orally to 15 healthy subjects for 2 weeks. However, there was no net decrease in the urinary excretion of oxalate, but a risk index based on the urinary content of calcium, magnesium, oxalate, citrate and urine became reduced during treatment. The urinary inhibition of calcium oxalate crystal growth was unaffected. It is concluded that there may be a potential in methenamine-hippurate for the treatment of calcium stone disease, which can only be evaluated, however, by a clinical trial in stone patients.
在肾钙结石病的各种治疗方法中，尚无证据表明有任何一种方法能降低尿草酸水平。马尿酸乌洛托品（希普雷克斯）已广泛用于治疗尿路感染，并且通过在大鼠身上使用对氨基马尿酸进行的微穿刺研究可以预期，它能减少肾脏对草酸的分泌。对15名健康受试者每日口服3克该药物，持续2周。然而，尿草酸排泄量并未出现净减少，但基于尿中钙、镁、草酸、柠檬酸盐含量以及尿量得出的风险指数在治疗期间有所降低。对草酸钙晶体生长的尿液抑制作用未受影响。得出的结论是，马尿酸乌洛托品在治疗钙结石病方面可能具有潜力，不过这只能通过对结石患者进行临床试验来评估。
